DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Product Launch
Aladdin Healthcare Technologies completes Biomedical Knowledge Graph for Commercial use In Drug Development
- Proprietary Knowledge Graph 'PharmaKG' released as Software As A Service (SAAS)
- PharmaKG makes key findings of potential drug candidates visible
- PharmaKG identifies target molecules, pathological causalities and new fields of application for drugs
- Great interest from customers in the USA, China and Norway
PharmaKG has been used by Aladdin and its partners to process biomedical knowledge and reasoning, to accelerate the discovery of artificial intelligence (AI) drugs. The PharmaKG allows to uncover key findings, mechanisms of action and potential drug candidates by revealing essential relationships between diseases, genes, chemical compounds or drugs. The Pharma Knowledge Graph offers key functions such as the identification of target molecules, the discovery of pathological causalities, the analysis of mechanisms and the repurposing of drugs to new fields of application.
Wade Menpes-Smith comments: "Aladdin's knowledge graphs help to discover new disease patterns and viral mechanisms to accelerate drug development in collaboration with pharmaceutical companies. Customers from China, the USA and Norway are already showing strong interest in the PharmaKG".
About Aladdin Healthcare Technologies SE
For further information:
Aladdin Healthcare Technologies Ltd.
21.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
Aladdin Healthcare Technologies SE
Unter den Linden 10
Regulated Market in Dusseldorf
EQS News ID:
End of News
DGAP News Service